MyFinsight
Home
Blog
About
Income Statement
|
Cash Flow
|
Balance Sheet
|
Ratios
Cash Flow Overview
Change in Cash
$46,688K
Free Cash flow
$59,560K
Unit: Thousand (K) dollars
Positive Cash Flow Breakdown
Net income
Amortization of intangible asset...
Proceeds from exercise of stock ...
Others
Negative Cash Flow Breakdown
Repurchase of common stock
Accrued expenses and other liabi...
Change in fair value of equity s...
Others
Subscribe for Financial Insights
Page 1
Quarterly
123
Page 1
Cash Flow
2026-03-31
2025-12-31
2025-09-30
2025-06-30
Net income
63,734
52,698
52,783
108,845
Depreciation
70
72
72
231
Stock-based compensation
6,260
5,661
5,670
13,447
Amortization of intangible assets
9,703
9,465
9,344
18,689
Inventory reserve and write-offs
-
83
-292
673
Deferred taxes
2,336
4,511
-2,417
4,755
Accretion of discount
135
116
96
138
Reduction in the carrying amount of right-of-use asset
77
75
74
146
Acquired inventory samples expensed from asset acquisition
-
0
-
-
Acquired in-process research and development
-
0
-
-
Change in fair value of equity securities
4,750
3,369
-2,089
-308
Accounts receivable, net
4,357
20,068
40,546
387
Inventory
-2,236
9,220
9,087
-218
Prepaid expenses and other current assets
-2,449
-6,907
6,697
387
Accounts payable
-4,051
2,106
3,568
-11,065
Accrued expenses and other liabilities
-9,207
5,210
13,241
5,713
Operating lease liability
-106
-102
-102
-197
Net cash provided by (used in) operating activities
59,587
44,891
32,438
131,341
Purchases of property and equipment
27
32
0
26
Payments in connection with asset acquisitions
-
0
-
-
Acquisition of in-process research and development
-
0
-
-
Purchase of equity securities
-
0
-
-
Proceeds from issuance of common stock
-
0
0
0
Net cash provided by (used in) investing activities
-27
-32
0
-26
Payment of employee withholding tax related to stock-based compensation
301
912
0
861
Proceeds from exercise of stock options
3,302
1,876
5,796
6,997
Payment of fees in connection with issuance of common stock
-
0
0
0
Repurchase of common stock
14,574
25,300
-
-
Payment of liabilities arising from asset acquisition
1,299
1,244
1,142
2,204
Net cash provided by (used in) financing activities
-12,872
-25,580
4,654
3,932
Net increase (decrease) in cash and cash equivalents
46,688
19,279
37,092
135,247
Cash and cash equivalents beginning of period
709,171
689,892
517,553
-
Cash and cash equivalents end of period
755,859
709,171
689,892
-
Page 1
Unit: Thousand (K) dollars (except for numbers of shares and EPS). Numbers labeled with * are estimated quarterly values.
Page 1
Buy us a coffee
Time Plot
Show the time plot by selecting a row from the table.
Cash Flow
Net income
$63,734K
Amortization of intangible
assets
$9,703K
Stock-based compensation
$6,260K
Prepaid expenses and
other current assets
-$2,449K
Inventory
-$2,236K
Reduction in the carrying
amount of right-of-use...
$77K
Depreciation
$70K
Net cash provided by
(used in) operating...
$59,587K
Canceled cashflow
$24,942K
Net increase
(decrease) in cash and cash...
$46,688K
Canceled cashflow
$12,899K
Accrued expenses and
other liabilities
-$9,207K
Change in fair value of
equity securities
$4,750K
Accounts receivable, net
$4,357K
Accounts payable
-$4,051K
Deferred taxes
$2,336K
Accretion of discount
$135K
Operating lease liability
-$106K
Proceeds from exercise of
stock options
$3,302K
Net cash provided by
(used in) financing...
-$12,872K
Net cash provided by
(used in) investing...
-$27K
Canceled cashflow
$3,302K
Repurchase of common stock
$14,574K
Purchases of property and
equipment
$27K
Payment of liabilities
arising from asset...
$1,299K
Payment of employee
withholding tax related to...
$301K
Buy us a coffee
CATALYST PHARMACEUTICALS, INC. (CPRX)
CATALYST PHARMACEUTICALS, INC. (CPRX)